GlassScriptPhysician profile
Sarah Farber
NPI 1740916097
$4,010.47
in general payments reported to CMS, 2019-2025
24 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $329 · 2023: $1,340 · 2024: $1,281 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,573 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.99 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,672.69 | 2022-2025 | |
| Janssen Biotech, INC. | $327.34 | 2023-2025 | Stelara, Tremfya |
| Nestle Healthcare Nutrition INC. | $304.82 | 2022-2023 | |
| Genzyme Corporation | $247.21 | 2022-2025 | |
| Madrigal Pharmaceuticals | $214.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $199.86 | 2022-2025 | Entyvio, Gattex |
| Celgene Corporation | $183.32 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.74 | 2022-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $93.17 | 2024 | |
| Ardelyx, INC. | $80.05 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $79.42 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $79.28 | 2023-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $59.51 | 2022-2023 | Dificid |
| Organon LLC | $51.17 | 2023-2024 | Renflexis, Hadlima |
| Regeneron Healthcare Solutions, INC. | $49.24 | 2023-2024 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.26 | 2025 | |
| Aimmune Therapeutics, INC. | $31.77 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.40 | 2024 | Cyltezo |
| Lilly USA, LLC | $22.10 | 2024 | Omvoh |
| Celltrion USA INC. | $21.98 | 2025 | Vegzelma |
| Astrazeneca Pharmaceuticals LP | $19.25 | 2023 | Imfinzi |
| Daiichi Sankyo INC. | $16.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $13.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.